Sonova Holding AGFull report →1 / 14
SOONSIXThe short version

Sonova Holding AG

Sonova is the world's largest hearing-aid maker — Phonak, Unitron, Advanced Bionics and a large retail network — a Swiss blue-chip whose sales, margins and share price have all stepped down since a 2021 peak.

Over the past six months the shares fell from CHF 221 in January to a CHF 168 low in late March, then recovered to CHF 209 — still about half the late-2021 peak.
CHF 209
Share price
CHF 12.5bn
Market cap
CHF 3.61bn
FY2026 sales
17.4%
Founder ownership
SwipeScroll▾
The statements

Flat sales, a four-point margin step-down, cash intact

FY2022 → FY2026as reported · CHF
RevenueCHF3.6B−7%
Operating margin18.7%+0.8pp
Net incomeCHF439M−20%
EPSCHF7.22−20%
Free cash flowCHF656M+0%
Open the full statements →
Fiscal year ends 31 March; FY2026 figures are continuing operations.
  • Sales went sideways. After a post-pandemic surge, group revenue held near CHF 3.6bn for four years; continuing-operations sales were CHF 3,605.9m in FY2026 — down 0.2% in francs, up 5.9% in local currency.
  • Margins stepped down, then steadied. Reported EBIT margin fell from 22.6% in FY2022 to 18.7% in FY2026; the normalized EBITA margin troughed at 20.6% in FY2024 and has recovered to 22.5%.
  • Cash held up. Free cash flow was CHF 473.7m in FY2026 and net debt fell to CHF 994.3m, about 1.2x normalized operating profit; the dividend rose to a record CHF 4.70.
Consumer Hearing (Sennheiser) was reclassified to discontinued operations in FY2026.
The growth engine

A widening Wholesale lead, won on a shrinking R&D budget

Latest-year hearing-aid growth, local currency
A ~7pp lead delivered as R&D intensity fell from 6.8% to 6.0% of sales.
  • The finding. Sonova's growth engine is an accelerating, high-margin Wholesale franchise (+9.5% local, segment margin up to 23.7%) but its ~7pp lead over Demant (+2% organic) was delivered on falling R&D intensity (6.8% -> 6.0% of sales), so the Sphere lead is a timing edge to be re-won every two to three years rather than a structural, spend-driven moat.
  • The counter. Rivals already ship on-device AI — Oticon Intent arrived in early 2024, before Sphere — and the falling R&D intensity may be operating leverage on a front-loaded six-year DEEPSONIC build, extended by Infinio Ultra in October 2025.
  • Why it matters. The exit multiple, not EPS, drives the two-year return: Wholesale growth converging toward the 4–6% market points to a bear ~16x case worth about a 15% loss, while a sustained premium supports a re-rating.
What backs the equity

A questionable capital record, sitting over no asset floor

FY2026 shareholders' equity, by asset backing
Equity of CHF 2,635.8m at 31 March 2026; goodwill alone is ~87%.
  • The finding. Sonova spent ~CHF 1.45bn near the cycle top — CHF 1.12bn of buybacks at ~CHF 317 and CHF 325.5m on Sennheiser now exiting at a CHF 106.5m loss — on top of an equity base that is ~100% intangible (tangible book CHF 14.8m, goodwill ~87% of the CHF 2,636m equity), so a questionable capital-allocation record sits over no asset floor.
  • The counter. Net debt fell from CHF 1,495.9m to CHF 994.3m, ROCE is 19.0%, buybacks shrank the share count about 7.4%, and the goodwill clears its impairment tests with a pre-tax WACC raised to 10.9% and a 1pp cushion to spare.
  • Where safety sits. With tangible book at CHF 14.8m there is no book-value floor; downside protection rests on net debt near 1.2x normalized EBITA and ~95% cash conversion, not on assets.
The demand backdrop

A low-penetration market that ages in the company's favour

~430M
People with moderate-or-worse hearing loss
4–6%
Structural hearing-aid market growth per year
32%
Developed-market adoptionjust 2% in China & India
  • Demand is durable. About 1.5 billion people live with some hearing loss and roughly 430 million have moderate-or-worse loss; most go untreated, and the treated population grows as societies age.
  • Penetration is the runway. Developed markets fit hearing aids to about a third of those who need them; in China and India it is nearer 2%, leaving a long adoption curve ahead.
Moat and OTC threat

A standing margin lead over Demant, and the OTC question

Normalized operating margin: Sonova vs Demant
YearSonova EBITA%Demant EBIT%
FY202224.7%20.5%
FY202322.1%16.3%
FY202420.6%20.9%
FY202521.6%19.6%
FY202622.5%17.2%
Sonova on normalized EBITA, Demant on reported EBIT; peer years lag Sonova's by one.
  • The margin gap persists. Sonova's normalized EBITA margin has sat above Demant's operating margin in four of the last five years, widening again to 22.5% versus 17.2% most recently.
  • The OTC threat is bounded, so far. U.S. regulators cleared AirPods-as-hearing-aid software in September 2024, but OTC targets milder loss than Sonova's prescription base; the effect has been additive, not substitutive.
  • Share gains held through the downturn. Sonova kept taking prescription share while the multiple de-rated — evidence its franchise did not break.
Segment economics

One big prescription franchise, one small implant business

FY2026 external sales by channel
Hearing Instruments is 93% of sales and about 98% of segment profit.
  • Wholesale plus retail is the engine. The Hearing Instruments segment — prescription devices sold wholesale and through owned stores — is CHF 3,353.8m of sales and nearly all the profit.
  • Cochlear Implants is small and shrinking. Implant sales fell to CHF 252.1m in FY2026, down 11.1% in local currency; it is 7% of sales and about 2% of profit.
  • Little of the top line is bought. Growth is overwhelmingly organic rather than acquired — the reassurance for an owner asking how much revenue is earned versus purchased.
The currency wedge

Real growth in local currency, masked by a strong franc

FY2026 growth: local currency vs reported francs
The franc turned +5.9% local sales into roughly flat reported sales.
  • The franc hides the operating result. Local-currency sales rose 5.9% and normalized EBITA 17.3%, yet in francs those became -0.2% and +3.7%; currency cut normalized EBITA by about CHF 106.5m.
  • A franc-paying owner banks the reported line. On reported figures, EPS including discontinued operations fell about 20% and ROCE eased from 24.1% to 19.0% — the translation drag is real to a Swiss shareholder.
  • What decides it. Whether the franc drag persists or reverses is largely exogenous; it is worth watching rather than forecasting.
Owners and stewards

Founders hold the largest block; the stewards bought high

Largest shareholders
HolderStake
Diethelm family (founder)11.26%
Rihs family (founder)6.18%
UBS Fund Management5.48%
BlackRock5.10%
Board + management0.10%
Founding families together hold ~17.4%; the board and management own ~0.10%.
  • Skin in the game is founder, not manager. The Diethelm and Rihs families hold about 17.4% — worth roughly CHF 2.2bn — while the board and executives own about 0.10% combined.
  • Pay is modest and gated. The CEO's total was CHF 2.61m and the say-on-pay vote passed with about 90% support; compensation is tied to ROCE.
  • The buybacks were mistimed. Sonova repurchased stock at ~CHF 337 and ~CHF 291 in FY2022-23, well above today's CHF 209; none have run since FY2024.
Capital returns

A rising dividend, but buybacks stopped after the cycle top

Capital returned to shareholders (CHF m)
CHF 1.12bn of buybacks in FY2022-23; none since.
  • The dividend never blinked. Distributions rose through the entire de-rating to a record CHF 4.70 per share, one cut aside across five years.
  • Buybacks lapsed at the wrong time. After spending CHF 1.12bn near the top, the programme went quiet; restarting near CHF 209 would read as a stewardship upgrade.
  • The forward view is modest growth. Consensus sees sales reaching about CHF 4.04bn and EPS near CHF 11.4 by FY2028 — roughly 8% annual EPS growth.
What the price implies

The fall was mostly multiple, not earnings

From the 2021 peak to today
PointPriceP/E
31 Mar 2022 closeCHF 387.6036.7x
Late-2021 peak (market data)~CHF 40238.0x
23 Jul 2026CHF 209.420.1x
Normalized EPS barely moved (CHF 10.57 to 10.42); the multiple roughly halved.
  • Multiple did the work. The ~46–48% de-rating came almost entirely from a lower P/E — normalized continuing EPS is essentially unchanged over the period.
  • The price already assumes little. At CHF 209 the shares imply only about 4% long-run growth, giving no credit for share gains or buybacks.
  • The debate is the exit multiple. Whether about 20x is a cyclical trough or the new normal for a stepped-down franchise is what the report weighs.
Valuation

Priced like a slow compounder, not a fallen growth name

20.7x
Forward P/E (FY2027E)
16.6x
EV / normalized EBITA
4.2%
Operating free-cash-flow yield
2.2%
Dividend yield
  • Cheaper than its own history, dearer than Demant. Roughly 20x forward earnings sits well below the ~38x 2021 peak but above a re-rated-down Demant.
  • Yield support builds as debt falls. The 4.2% operating free-cash-flow yield rises toward 5% on FY2027 estimates as net debt keeps shrinking.
EV of about CHF 13.5bn over CHF 811.2m normalized EBITA.
Scenarios

Two years out, the exit multiple decides the outcome

FY2028 price scenarios
Total returns of about -15%, +18% and +48% including dividends.
  • The spread is wide and multiple-driven. A ~50% swing in the exit multiple moves the two-year return far more than the ~19% swing in EPS across the cases.
  • Downside is buffered, not floored. The bear case is about a 15% loss, cushioned by low leverage and cash generation rather than by any asset value.
  • The bull needs the premium to hold. A re-rating toward 24x on sustained share gains delivers roughly a 48% total return.
What to watch

A cash-rich leader at half its old multiple: durable franchise overpunished, or a permanent step-down.

Read the full report →

This distills a guided study built chapter by chapter — from the statements through the moat, the capital record, and what the price implies.

Compiled from the full report · 2026-07-24 · For information, not investment advice.